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Abstract: Hepatitis C virus (HCV) establishes a persistent infection in more than 70% of 
infected individuals. This striking ability to evade the powerful innate immune system 
results from viral interference occurring at several levels of the interferon (IFN) system. 
There is strong evidence from cell culture experiments that HCV can inhibit the induction of 
IFNβ by cleaving important proteins in the virus sensory pathways of cells such as MAVS 
and TRIF. There is also evidence that HCV interferes with IFNα signaling through the  
Jak-STAT pathway, and that HCV proteins target IFN effector systems such as protein 
kinase R (PKR). These in vitro findings will have to be confirmed in clinical trials 
investigating the molecular mechanisms of HCV interference with the innate immune 
system in liver samples. 
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1. Introduction 
Hepatitis C virus (HCV) infection persists in more than 70% of exposed individuals. The ability of 
HCV to persist within a host is striking, and is believed to be due to numerous efficient mechanisms by 
which the virus evades the immune response of the host. Type 1 interferons (IFNs) are crucial 
cytokines in innate immunity. HCV interferes with all aspects of the IFN system: with the induction of 
IFNβ in infected cells, with IFNα/β signaling through the Jak-STAT pathway, and with IFN induced 
proteins with antiviral properties. 
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2. Interferons 
IFN was identified more than 50 years ago by Isaacs and Lindenmann during their studies of the 
phenomenon of viral interference, the ability of an active or inactivated virus to interfere with the 
growth of an unrelated virus [1]. Today, more than 10 mammalian IFN species and numerous 
subspecies have been discovered, each with individual properties, but all having antiviral activity [2]. 
They are currently classified into three groups: type I, type II and type III IFNs. The type I IFNs 
include all IFN-αs, IFN-β, IFN-ε, IFN-κ, IFN-ω and IFN-ν [3]. Humans have 12 different IFN-αs and a 
single IFN-β. Type I IFN genes are clustered on the human chromosome 9. Each subtype is encoded 
by its own gene and regulated by its own promoter, and none of them contain introns [3]. The different 
IFN-αs and IFN-β have substantial differences in their specific antiviral activities and in the ratios of 
antiviral to antiproliferative activities. However, the molecular basis of these differences is not yet 
known. All type I IFNs bind to the same interferon alpha/beta receptor (IFNAR) that consists of two 
major subunits: IFNAR1 (the a subunit in the older literature) [4] and IFNAR2c   
(the βL subunit) [5,6].  
There is only one class II IFN, IFN-γ. IFNγ is produced by T lymphocytes when stimulated with 
antigens or mitogens. IFNγ binds to a distinct receptor, the interferon gamma receptor (IFNGR), that 
consists of the two subunits IFNGR1 (previously α chain) [7] and IFNGR2 (previously β chain or 
accessory factor) [8,9]. 
The recently described type III IFNs IFN-λ2, IFN-λ3 and IFN-λ1 are also known as IL-28A, IL-28B 
and IL29, respectively. Same as type I IFNs, they are also induced by viral infections [10]. They signal 
through the IFN-λ receptor consisting of the IL-10R2 chain that is shared with the IL-10 receptor, and 
a unique IFN-λ chain [11,12]. The recent discovery that a genetic polymorphism near the IL28B gene, 
encoding IFN-λ3, is associated with an approximately twofold change in response to treatment with 
pegylated IFNα/ribavirin provides strong evidence that type III IFNs are important for the control of 
HCV [13-15]. 
3. Induction of Type I Interferons 
Cells produce IFN-αs and IFN-β in response to infection by a variety of viruses. Unlike bacteria and 
fungi, which have microbe-specific structures distinguishable from host cell structures, viruses are 
made predominantly of host-derived components. Given the lack of virus specific proteins or lipids, 
the cellular receptors that detect viruses have instead evolved to recognize the presence of the viral 
genome composed of nucleic acids. Two important pathways that detect viral genomes and induce 
type I IFNs have been discovered and characterized during recent years: the toll-like receptor (TLR) 
dependent pathway [16,17] and the cytosolic pathway triggered by binding of viral RNA to the RNA 
helicases retinoic acid inducible gene-I (RIG-I) and melanoma differentiation antigen 5 (MDA5) 
[18,19]. 
TLRs are a family of transmembrane pattern recognition receptors (PRRs) that recognize microbial 
pathogen associated molecular patterns (PAMPs) and activate the expression of genes involved in 
inflammatory and immune responses [17]. There are at least 10 human TLRs, and 3 of them are 
involved in the recognition of viral infections: TLR3, TLR7 and TLR9. TLRs are expressed on various 
immune cells such as macrophages, dendritic cells (DCs), B cells, but also on fibroblasts and epithelial Viruses 2009, 1                                       
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cells. While TLRs involved in the recognition of bacterial components are expressed on the cell 
surface, TLR3, TLR7 and TLR9 are localized in intracellular compartments such as endosomes. TLR3 
recognizes dsRNA (e.g. HCV-RNA)[20], TLR7 detects ssRNA [21,22] and TLR9 interacts with 
unmethylated DNA with CpG motifs [23]. TLR activation induces signaling cascades that mainly 
involve the key transcription factors NF-κB and various interferon regulatory factors (IRFs) (Figure 1). 
Specifically, IRF3 and IRF7 have both distinct and essential roles for virus induced transcriptional 
activation of IFN-β [24]. IRF3 is constitutively expressed in most cells, whereas IRF7 is expressed at 
low amounts and is strongly expressed only after stimulation of cells with type I IFNs [25]. A notable 
exception to this rule are the plasmocytoid dendritic cells that have high constitutive expression levels 
of IRF7 [10,26,27]. TLR3 uses the adapter protein TRIF and the kinase TBK1 to mainly activate IRF3 
in conventional DCs and macrophages, whereas TLR7 and TLR9 induce the expression and secretion 
of large amounts of type I IFNs in plasmacytoid DCs through the adaptor molecule MyD88 that 
directly interacts with IRF7 (not IRF3) [28,29]. The MyD88 pathway requires the IRAK4-IRAK1-
IKKα kinase cascade to activate both IRF7 and the NF-κB pathway [30]. 
Figure 1. Induction of IFNβ by viral infections. 
 
 
The cytosolic pathway of type I IFN induction is initiated by the recognition of viral 5’triphosphate 
RNA and dsRNA by RIG-I and MDA5. Binding of viral RNA leads to a conformational change of 
these sensors that results in their binding to MAVS (also called IPS-1, Cardif, VISA), an essential 
downstream adaptor in the cytosolic pathway [31-34]. Through as yet unidentified mediators, MAVS 
propagates the signal to the TBK1 and IKKi kinases that finally activate IRF3 and NF-κB (Figure 1). 
Activated IRF3, NF-κB and ATF2/c-jun bind to the IFN-β gene promoter and induce gene 
transcription. IFN-β is secreted by the cells, and binds to the IFNAR in an autocrine or paracrine way. Viruses 2009, 1                                       
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The activation of the Jak-STAT pathway upon IFNAR binding by IFN-β induces an important positive 
feedback loop that allows a very rapid and strong induction of an antiviral state in the infected cells 
and their neighbors (Figure 1). 
4. HCV Interference with Cellular Sensors 
The infection of cells with HCV leads to the induction of IFN-β through activation of the RIG-I and 
TLR3 pathways [19,35,36]. Interestingly, the HCV NS3/4A protease has been shown to cleave and 
inactivate MAVS (Cardif, IPS-1, VISA) and TRIF, two important adaptor proteins in the RIG-I and 
the TLR3 pathway, respectively [32,35]. The inhibition of these cellular sensors could be one of the 
factors contributing to viral persistence. However, as outlined in the next paragraph, HCV infection 
actually induces the endogenous IFN system despite HCV’s ability to cleave TRIF and MAVS. 
5. Induction of Interferon Stimulated Genes by HCV 
Hepatic gene expression studies with chimpanzees and humans provide compelling evidence that 
the inhibition of IFN-β induction, by cleavage of MAVS and/or TRIF, is in many cases incomplete and 
cannot prevent the activation of the endogenous IFN system in the liver. Acute infection of 
chimpanzees with HCV leads to the rapid activation of the endogenous IFN system [37]. Moreover, 
chronically HCV infected chimpanzees have an ongoing induction of a large number of   
IFN-stimulated genes (ISGs) in the liver, suggesting a continuous stimulation of the endogenous IFN 
system [38]. Interestingly, a single chimpanzee infected with a genotype (GT) 3 HCV showed less 
induction of ISGs compared to genotype 1 infected animals [38]. Many patients with chronic hepatitis 
C (CHC) also have a permanent induction of ISGs in the liver [39-41]. There is a strong association 
between such pre-activation of the endogenous IFN system and the failure to respond to 
pegIFNα/ribavirin therapy [39-41]. Interestingly, patients with a pre-activated IFN system have ISG 
expression levels comparable to those achieved in responders by the treatment with pegIFNα, and it is 
presently not known, why such a high expression level of ISGs in pre-activated patients does not 
induce a spontaneous clearance of HCV [40]. Patients with GT 1 infections significantly more often 
had a pre-activated IFN system than those infected with GTs 2 and 3, providing a possible explanation 
why the treatment is more often successful in the latter group [40]. 
6. Interferon signaling through the Jak-STAT pathway 
6.1. The receptor-kinase complex 
All type I IFNs bind to the same interferon alpha/beta receptor (IFNAR) that consists of two major 
subunits: IFNAR1 (the a subunit in the older literature) [4] and IFNAR2c (the βL subunit) [5,6]. Each 
receptor subunit constitutively binds to a single specific member of the Janus kinase (Jak) family: 
IFNAR1 to tyrosine kinase 2 (TYK2) and IFNAR2c to JAK1. When type I IFNs bind to the two 
receptor chains, TYK2 and JAK1 transactivate each other by mutual tyrosine phosphorylation, and 
then initiate a cascade of tyrosine phosphorylation events on the intracellular domains of the receptors 
and on signal transducer and activator of transcription (STAT) 1, STAT2 and STAT3. Viruses 2009, 1                                       
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6.2. Signal Transducers and Activators of Transcription (STATs) 
In most cells, type I IFNs activate STAT1, STAT2 and STAT3. STAT1 and STAT2 combine with a 
third transcription factor, IRF9, to form interferon stimulated gene factor 3 (ISGF3). ISGF3 binds to 
interferon stimulated response elements (ISREs) in the promoters of ISGs. Alternatively, IFN activated 
STAT1 and STAT3 can form homodimers or STAT1-STAT3 heterodimers. These STAT dimers bind 
a different class of response elements, the gamma activated sequence (GAS) elements. Once bound to 
the promoters of ISGs, STATs induce the transcription of genes involved in the generation of an 
antiviral state (Figure 2) [42,43]. 
Figure 2. Type I IFNs signal through the Jak-STAT pathway. PTP1B, protein tyrosine 
phosphatase 1B; SHP1/2, SH2 domain-containing protein tyrosine phosphatase1 or 2; 
TCPTP, T cell protein tyrosine phosphatase. 
 
 
STAT proteins are composed of 750 to 850 amino acids. They share well-defined, structurally and 
functionally conserved domains including the amino-terminal (NH2), coiled-coil, DNA-binding, 
linker, SH2, tyrosine activation, and transcriptional activation domains [44]. Viruses 2009, 1                                       
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6.3. Negative Regulators of Interferon Signaling 
6.3.1. Suppressor of Cytokine Signaling (SOCS) 
SOCS proteins are important negative regulators of Jak-STAT signaling [45]. The family consists 
of eight members, CIS and SOCS1 to SOCS7. CIS, SOCS1, SOCS2 and SOCS3 are induced by a large 
number of cytokines and inhibit cytokine receptors in a negative feedback loop. Type I IFNs induce 
SOCS1 and SOCS3 [46], and overexpression experiments have demonstrated that both inhibit IFN 
signaling through the Jak-STAT pathway [46,47]. SOCS1-deficient mice develop severe inflammatory 
disease because of IFN-γ hypersensitivity [48], but are very resistant to viral infections, most likely 
because of enhanced type I IFN signaling [49]. 
6.3.2. USP18 
Ubiquitin specific peptidase 18 (USP18/UBP43) is another important negative regulator in type I 
IFN signaling. USP18/UBP43 was originally identified as a protease cleaving ubiquitin-like modifier 
ISG15 from target proteins, but was recently found to play a negative regulatory role independently of 
its ISG-deconjugating ability [50,51]. UBP43 was reported to inhibit the activation of JAK1 by 
interfering with the binding of JAK1 to IFNAR2c [52]. UBP43 deficient mice show a severe 
phenotype characterized by brain cell injury, poly-I:C hypersensitivity, and premature death [53,54]. 
Interestingly, they are resistant to otherwise fatal cerebral infections with LCMV and VSV [55]. 
USP18/UBP43 is also important for long-term refractoriness of the IFN system [56]. 
6.3.3. Protein Inhibitor of Activated STAT1 (PIAS1) and PIAS3 
PIAS1 and PIAS3 specifically bind to tyrosine phosphorylated STAT1 and STAT3, respectively, 
and inhibit the DNA-binding of STAT dimers [57]. PIAS1 selectively inhibits interferon-inducible 
genes and is important in innate immunity. As a consequence, PIAS1 deficient mice show increased 
protection against pathogenic infection [58]. 
6.3.4. TcPTP 
STAT1 is deactivated in the nucleaus by dephosphorylation of the tyrosine 701 by T cell protein 
tyrosine phosphatase (TcPTP) [59]. TcPTP deficient mice develop progressive systemic inflammatory 
disease as shown by chronic myocarditis, gastritis, nephritis, and sialadenitis as well as elevated serum 
IFN-γ [60]. 
7. Interference of HCV with IFN Signaling through the Jak-STAT pathway 
In order to escape from the powerful antiviral effects of the IFN system, many viruses have evolved 
strategies to block IFN signal transduction [61,62]. Interference of HCV with IFN signaling has been 
suggested in several studies, sometimes with controversial results [63,64]. One proposed mechanism is 
the inhibition of STAT1 activation through an upregulation of SOCS3 by HCV core protein, which has 
been found after transient transfection of HepG2 and Huh7 cells [65,66]. Another group reported that 
the expression of HCV proteins in Huh7 cells leads to a proteasome-dependent degradation of STAT1 Viruses 2009, 1                                       
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[67]. A third group, also using HCV protein expression in Huh7 cells, reported normal STAT1 
expression and phosphorylation, but an inhibition of nuclear translocation of phosphorylated STAT1 
[68]. A fourth group reported found reduced STAT3 expression levels in livers of patients with chronic 
hepatitis C and reported that HCV expression in Huh7 cells inhibited IFN-α induced phosphorylation 
of STAT1, STAT2 and STAT3 [69]. We have found an inhibition of DNA binding of activated STATs 
not only in cells transfected with the HCV genome, but also in the liver of HCV transgenic mice, and 
in liver biopsies of patients with CHC [70,71]. In all cases, STAT1 protein expression and tyrosine 
phosphorylation were not impaired.  
Figure 3. HCV induces the over-expression of PP2Ac via an ER stress response pathway. 
PP2A inhibits PRMT1, the enzyme responsible for STAT1 methylation. The resulting 
hypomethylation of STAT1 facilitates the binding of PIAS1, an inhibitor of DNA binding 
of activated STAT1. Tyrosine phosphorylation is shown by Y, and arginine methylation  
by R. 
 
 
Further investigations of the molecular mechanisms of HCV interference with IFN signaling 
identified protein phosphatase 2A (PP2A) as an important mediator in the inhibitory pathway [72]. The 
catalytic subunit of PP2A, PP2Ac, was found to be overexpressed as a result of an endoplasmatic 
reticulum (ER) stress response induced by HCV protein expression [73]. PP2Ac was overexpressed in 
cells after HCV protein expression, in liver extracts of HCV transgenic mice, and in liver biopsies of 
patients with CHC [72]. Furthermore, expression of a constitutive active form of PP2Ac in Huh7 cells 
resulted in an inhibition of STAT1 DNA binding [72]. PP2A can directly bind to protein arginine Viruses 2009, 1                                       
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methyltransferase 1 (PRMT1) and inhibit its enzymatic activity [74]. This inhibition of PRMT1 results 
in a decreased methylation of a number of proteins, amongst them STAT1 [72]. It has been reported 
that the arginine methylation of STAT1 regulates the association of STAT1 with the inhibitor PIAS1 
[75], a finding that is still controversial [76]. Nonetheless, we have found that inhibition of PRMT1 by 
increased expression of PP2Ac leads to an increased association of STAT1 with PIAS1, a finding that 
could well explain the impaired DNA binding of activated STATs in HCV infected cells [72]. 
Interestingly, treatment of cells with the methyl group donor S-adenosyl-methionine restored normal 
IFN signaling in cells with HCV protein expression and increased the potency of IFNα in the HCV 
replicon system [77]. Our current working model of HCV interference with IFN signaling is shown in 
Figure 3. 
8. Effects of Type I Interferons 
Interferons exhibit a wide spectrum of biological activities in target cells, including antiviral, 
immunomodulatory, antiangiogenic, and growth inhibitory effects. They exert their effects mainly 
through Jak-STAT mediated regulation of gene transcription. However, there are also Jak-STAT 
independent effects, notably the activation of the p38 Map kinase signaling cascade [78,79], and the 
activation of the phosphatidylinositol 3 (PI3) kinase – Akt kinase – mTOR/p70 S6 kinase pathway that 
regulates mRNA translation [80,81]. 
8.1. Interferon Regulated Genes 
Stimulation of cells with type I IFNs usually leads to the induction of several hundred genes   
(IFN stimulated genes, ISGs), but there are also some genes that are negatively regulated by IFNs 
[40,82,83]. There is considerable variation between different cell types in regard to the number and 
also the identity of the regulated genes [83]. Gene expression analysis in human and chimpanzee have 
shown that systemic administration of (pegylated) IFNα induces overlapping but clearly distinct sets of 
genes in liver and peripheral blood mononuclear cells (PBMCs) [40,84]. The mRNA levels of most of 
the genes are increased 2 to 10 fold by IFN stimulation, but some genes are induced even stronger 
[40]. In the liver, most of the ISGs are upregulated within hours after administration of pegylated IFNα 
and rapidly downregulated again within the first 8 to 24 hours [84]. 
8.2. Antiviral Effects 
Type I IFN induced regulation of hundreds of genes establishes an “antiviral state” in the cell 
[85,86]. The term “antiviral state” implies protection of the cell against viral infection, but it is a 
generic term, and the lack of precise criteria for its definition reflects the fact that we still have only an 
elementary understanding of what exactly it is. Indeed, a large number of these regulated genes have as 
yet unknown functions. Some ISGs have broad antiviral effects. For example, protein kinase R (PKR), 
a member of the eukaryotic initiation factor 2α (eIF2α) kinase family, phosphorylates eIF2α with a 
consequent blockade of translation of most cellular and viral mRNAs [87]. Members of the interferon-
induced protein with tetratricopeptide repeats (IFIT1 (ISG56) and IFIT2 (ISG54)) also inhibit 
translation by binding to eIF3 [88]. Another well-studied antiviral effector is 2’-5’ oligoadenylate Viruses 2009, 1                                       
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synthetase (OAS). Both the gene transcription and the enzymatic activity are regulated: the enzymatic 
activity is stimulated by viral dsRNA, and OAS expression is upregulated several-fold by IFN-α. The 
2’-5’oligoadenylates produced by activated OAS in turn activate the latent RNA nuclease RNase L, 
resulting in the degradation of viral and host RNAs [87]. Recently, the ISG15 system has been found 
to be another broadly active non-specific antiviral effector. ISG15 is one of the most prominent ISGs. 
It is an ubiquitin-like protein that conjugates to more than 150 cellular target proteins [55,89-91]. The 
conjugation is executed by an enzymatic cascade that includes an E1 activating enzyme (UBE1L) [92], 
an E2 conjugating enzyme (UbcH8) [93,94], and an E3 ligase (HERC5 and TRIM25) [95,96]. The 
conjugation can be reversed by ubiquitin protease 43 (UBP43, also known as USP18) [51]. All these 
enzymes are induced by type I IFNs. Many of the ISG15 target proteins have important roles in the 
IFN response, for example Jak1, STAT1, RIG-I, MxA, PKR and RNaseL [90]. Consistent with its role 
in the IFN system, mice deficient in ISG15 have increased susceptibility to infection with several 
viruses [97]. 
Several ISGs have been implicated in the host defence against hepatitis C virus (HCV). Viperin, a 
member of the radical S-adenosyl methionine domain containing enzymes, inhibits replication of HCV 
in the replicon system [98,99]. PKR and ISG20, a 3’-5’ exonuclease with a strong preference for 
single-stranded RNA, also strongly inhibit HCV replicons [99]. 
9. Interference of Hepatitis C Virus with Interferon Effector Systems 
The HCV protein NS5A was shown to inhibit PKR activation in cell culture [100]. In some 
populations, mutations in the so-called IFN sensitivity-determining region (ISDR) of HCV NS5A 
correlate with response to IFN treatments, and the ISDR is part of the PKR binding domain [101]. This 
finding, however, was not confirmed in other populations.  
Likewise, HCV E2 was shown to bind to PKR through a 12-amino acid sequence similar to the 
PKR autophosphorylation site and the eIF2α phosphorylation site, the PKR-eIF2α phosphorylation 
homology domain (PePHD). In this elegant work using transfected cells and yeast, E2 blocked the 
inhibitory effect of PKR on protein synthesis and cell growth. Interestingly, the homology of this  
12-amino acid sequence of E2 was found only in HCV GT 1a and 1b, but not GT 2a, 2b or 3a, 
providing a potential explanation for the better response rates obtained in patients with GT 2 or GT 3 
infections [102]. However, a clinical study could not find a significant correlation between the 
presence of this 12-amino acid motif and response to IFN therapy [103]. 
10. Conclusions 
HCV is exceptionally successful in establishing a persistent infection, and must have therefore 
evolved mechanisms to interfere with the powerful innate immune system. There is evidence mainly 
from cell culture work that HCV interferes with the induction of IFNβ in infected cells, with IFNα 
signaling trough the Jak-STAT pathway, and with IFN induced effector mechanisms, e.g. PKR. 
However, the significance of these mechanisms in vivo is less clear, and further work with liver biopsy 
samples obtained from patients treated within the framework of rigorously designed clinical trials will 
have to identify the mechanisms of viral interference that allow HCV to persist chronically in such a 
high percentage of infected individuals.  Viruses 2009, 1                                       
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